Reply to Gan et al

Affiliations

Comment

Fernando J Martinez. Am J Respir Crit Care Med. 2023.

. 2023 Nov 15;208(10):1141-1142.

doi: 10.1164/rccm.202309-1653LE.

¹ Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York.

No abstract available

Comment on

Icenticaftor, a Novel Treatment for Chronic Obstructive Pulmonary Disease, Needs Further Verification of Its Effectiveness.
Gan Q, Yang K, Wu Y, Wang J, Zhang H, Zhang N, Wu K. Gan Q, et al. Am J Respir Crit Care Med. 2023 Nov 15;208(10):1140-1141. doi: 10.1164/rccm.202307-1268LE. Am J Respir Crit Care Med. 2023. PMID: 37748186 Free PMC article. No abstract available.

1. Martinez FJ, Criner GJ, Gessner C, Jandl M, Scherbovsky F, Shinkai M, et al. Icenticaftor, a CFTR potentiator, in COPD: a multicenter, parallel-group, double-blind clinical trial. Am J Respir Crit Care Med . 2023;208:417–427. - PMC - PubMed
1. Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med . 2013;187:228–237. - PMC - PubMed
1. Kim V, Zhao H, Regan E, Han MK, Make BJ, Crapo JD, et al. COPDGene Investigators The St. George’s Respiratory Questionnaire definition of chronic bronchitis may be a better predictor of COPD exacerbations compared with the classic definition. Chest . 2019;156:685–695. - PMC - PubMed
1. Ferris BG. Epidemiology standardization project (American Thoracic Society) Am Rev Respir Dis . 1978;118:1–120. - PubMed
1. Fletcher CM, Clifton M, Fairbairn AS, Fry J, Gilson JC, Higgins ITT, et al. Standardized questionnaires on respiratory symptoms. Br Med J . 1960;2:1665.